YOLFTbeta
00

Yuhan Corp Preferred

000105 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

67,400.00KRW-100.00 (-0.15%)

Price History

Full chart

Market Stats

Previous Close67,500.00
Open67,500.00
Day Range66,900.00 – 68,800.00
52-Week Range55,100.00 – 114,572.67
Volume226
Market Cap4.81T
P/E (TTM)0.00
Forward P/E13.28
Dividend Yield0.95%
Beta0.42
50-Day Avg66,766.00
200-Day Avg78,842.50

About

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Wook-Je Cho
  • Employees2.08K
  • Headquarters74, Noryangjin-ro, Seoul, South Korea, Korea
  • Websitehttps://www.yuhan.co.kr

Leadership

  • Mr. Wook-Je ChoPresident, CEO & Executive Director · b. 1955
  • Mr. Yeul-Hong KimPresident, R&D Director & Executive Director · b. 1959
  • Mr. Byung-Man LeeVP, Head of the Mngt. HQ. & Internal Accounting Manager · b. 1958
  • Ms. Eunhee ParkMD & Director of Legal Affairs · b. 1971
  • Mr. Joo-Yong ChungMD & Head of Marketing Department · b. 1967
  • Mr. Jae-Kyo KimVP & Head of the Pharmaceutical Business Division · b. 1968
  • Mr. Sung-Soo KimMD & Head of the Lifestyle Health Business Division · b. 1964
  • Mr. Jun-Hwan KimMD & Head of Biopharmaceutical Division · b. 1975
  • Mr. Min Chul ChoMD & ESG Management Director · b. 1965
  • Mr. Chanhwan ParkMD & Head of Management Department · b. 1972

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.02T1.13T1.32T1.46T1.52T1.48T1.62T1.69T1.78T1.86T2.07T2.19T
Growth (%)-+10.93%+17.02%+10.71%+3.87%-2.53%+9.42%+4.19%+5.22%+4.68%+11.23%+5.75%
Cost of Revenue702.97B789.14B931.36B1.04T1.11T1.05T1.06T1.16T1.26T1.29T1.38T1.46T
Gross Profit314.52B339.59B389.44B424.62B413.79B430.85B558.42B524.65B518.20B565.86B689.39B729.92B
Gross Margin30.91%30.09%29.49%29.04%27.24%29.10%34.47%31.08%29.18%30.44%33.34%33.38%
Operating Expense240.13B253.75B291.65B335.91B363.67B418.32B474.17B476.05B482.17B508.83B634.51B625.54B
Operating Income74.39B85.84B97.79B88.71B50.13B12.54B84.26B48.60B36.03B57.03B54.88B104.37B
Operating Margin7.31%7.60%7.40%6.07%3.30%0.85%5.20%2.88%2.03%3.07%2.65%4.77%
EBITDA---201.73B152.06B116.68B302.39B181.68B141.41B185.52B139.20B307.23B
EBITDA Margin---13.80%10.01%7.88%18.67%10.76%7.96%9.98%6.73%14.05%
Net Income90.95B126.05B161.25B109.03B57.48B40.01B192.76B102.58B95.14B136.20B70.69B194.08B
Net Income Margin8.94%11.17%12.21%7.46%3.78%2.70%11.90%6.08%5.36%7.33%3.42%8.88%
R&D30.92B39.02B52.67B71.43B74.07B96.90B142.63B106.68B107.10B119.92B224.76B219.71B
R&D as % of Total Revenue3.04%3.46%3.99%4.89%4.88%6.55%8.81%6.32%6.03%6.45%10.87%10.05%
Interest Expense00003.67B3.10B2.71B2.94B3.47B6.30B14.73B15.40B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.24%0.21%0.17%0.17%0.20%0.34%0.71%0.70%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.62T1.88T2.05T2.09T2.17T2.12T2.39T2.46T2.47T2.40T2.94T3.22T
Total Liabilities340.11B516.39B549.39B488.35B522.08B467.21B547.02B527.92B464.92B419.38B791.38B858.64B
Total Equity1.27T1.36T1.50T1.60T1.64T1.65T1.84T1.93T1.99T1.98T2.10T2.31T
Cash155.68B221.81B244.85B256.61B241.30B274.22B353.49B253.59B293.04B239.05B306.48B348.56B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow94.39B126.23B74.14B126.13B93.45B65.99B28.83B99.00B99.53B127.75B54.60B106.23B
Investing Cash Flow-192.25B-117.79B-77.14B-42.24B-58.15B31.60B57.59B-167.14B15.62B---
Financing Cash Flow-16.39B57.39B23.30B-68.17B-51.38B-67.01B11.69B-36.53B-65.54B---
Capital Expenditure35.84B81.26B84.63B56.77B46.00B42.76B51.45B46.15B65.80B72.41B133.92B144.74B
Free Cash Flow---66.21B44.86B19.25B-62.35B17.13B5.15B55.35B-79.31B-38.51B
Dividends Paid15.63B18.04B20.55B20.75B21.94B22.91B23.78B24.94B26.08B27.27B32.15B37.48B
FCF to OCF---52.50%48.00%29.17%-216.25%17.30%5.18%43.32%-145.26%-36.25%
Dividend Paid to FCF---31.33%48.91%119.02%-38.14%145.63%506.34%49.27%-40.53%-97.33%

Earnings

Report DateMay 9, 2011Jul 29, 2011Nov 10, 2011Feb 29, 2012May 14, 2012Jul 27, 2012Nov 8, 2012Feb 27, 2013May 13, 2013Jul 26, 2013Nov 7, 2013Feb 26, 2014Apr 29, 2014Jul 29, 2014Oct 28, 2014Feb 25, 2015Apr 29, 2015Jul 29, 2015Oct 28, 2015Feb 22, 2016Apr 28, 2016Jul 27, 2016Oct 27, 2016Feb 21, 2017Apr 27, 2017Jul 28, 2017Nov 1, 2017Feb 20, 2018Apr 27, 2018Jul 27, 2018Oct 25, 2018Feb 19, 2019May 15, 2019Jul 31, 2019Nov 14, 2019Feb 25, 2020Apr 23, 2020Jul 29, 2020Nov 12, 2020Feb 24, 2021Apr 29, 2021Aug 17, 2021Oct 28, 2021Feb 22, 2022Apr 28, 2022Aug 16, 2022Nov 14, 2022Mar 15, 2023May 15, 2023Jul 28, 2023Oct 31, 2023Feb 6, 2024Apr 30, 2024Jul 30, 2024Oct 28, 2024Feb 12, 2025May 8, 2025Jul 28, 2025Oct 27, 2025Feb 11, 2026May 6, 2026Aug 14, 2026
EPS Estimate--------------------------------------------------------------
EPS Actual366.13243.39219.35342.11346.1532.92155.82361.56302.37320.71204.24286.73281.19345.01330.20231.65323.96406.85591.98337.14676.01449.31317.45717.44389.92423.30342.73297.54272.28214.96151.70116.64204.7771.82189.0064.271528.50447.50401.27167.45272.11451.01406.48227.23211.87453.36100.16500.92296.58115.74261.271198.51169.61427.81499.40-153.53117.79607.60338.181530.61361.72940.60
Surprise--------------------------------------------------------------
Timing----------------------------------------------------After-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap4.81T
Enterprise Value5.43T
Trailing P/E0.00
Forward P/E13.28
Price / Sales2.11
Price / Book2.07
Revenue (TTM)2.28T
Gross Profit (TTM)758.11B
EBITDA202.52B
Profit Margin10.39%
Operating Margin10.48%
Return on Equity9.51%
Return on Assets2.45%
Shares Outstanding1.15M
Shares Float61.76M
Beta0.42
Dividend Yield0.95%
Dividend Rate610.00
Payout Ratio19.24%

Dividends

20261×
610.00Feb 26, 2026
20241×
510.00Dec 27, 2024
20231×
460.00Dec 27, 2023
20221×
410.00Dec 28, 2022
20211×
410.00Dec 29, 2021
20201×
410.00Dec 29, 2020
20191×
410.00Dec 27, 2019
20181×
410.00Dec 27, 2018
20171×
410.00Dec 27, 2017
20161×
410.00Dec 28, 2016
20151×
410.00Dec 29, 2015
20141×
360.00Dec 29, 2014
20131×
310.00Dec 27, 2013
20121×
260.00Dec 27, 2012
20111×
260.00Dec 28, 2011
20101×
210.00Dec 29, 2010
20091×
210.00Dec 29, 2009
20081×
210.00Dec 29, 2008
20071×
210.00Dec 27, 2007
20061×
210.00Dec 27, 2006
20051×
210.00Dec 28, 2005
20041×
109.12Dec 29, 2004
20031×
109.12Dec 29, 2003
20021×
109.12Dec 27, 2002

Stock Splits

  • Apr 8, 20205:1